Pseudomonas aeruginosa virulence and therapy: Evolving translational strategies

Critical Care Medicine

Volumn 37, Issue 5, 2009, Pages 1777-1786

  Veesenmeyer, Jeffrey L ^a   Hauser, Alan R ^a   Lisboa, Thiago ^b   Rello, Jordi ^b  

^a NORTHWESTERN UNIVERSITY   (United States)

^b HOSPITAL UNIVERSITARI JOAN XXIII   (Spain)

Author keywords

Adjunctive therapy; Biofilms; Flagella; Pseudomonas aeruginosa; Quorum sensing; Type III secretion; Virulence factors

Indexed keywords

4 NITRO PYRIDINE N OXIDE; ACYL HOMOSERINE LACTONE ACYLASE; ACYL HOMOSERINE LACTONE LACTONASE; ALGINATE LYASE; ALKALOID DERIVATIVE; AMBROXOL; ANTIBIOTIC AGENT; AZITHROMYCIN; CHLORHEXIDINE; CYCLOHEXANONE DERIVATIVE; CYCLOPENTANOL; CYCLOPENTYLAMIDE; EDETIC ACID; FURANONE DERIVATIVE; GARLIC EXTRACT; LACTOFERRIN; LACTONE DERIVATIVE; MACROLIDE; NITRIC OXIDE; PATULIN; PENICILLIC ACID; PSEUDOMONIC ACID; S ADENOSYLCYSTEINE; S ADENOSYLHOMOCYSTEINE; SILVER; SINEFUNGIN; TETRAZOLE DERIVATIVE; TRANSFERRIN; TRICLOSAN; UNCLASSIFIED DRUG; URSENE TRITERPENE;

BACTERIAL VIRULENCE; BIOFILM; FLAGELLUM; HOSPITAL INFECTION; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTION; QUORUM SENSING; REVIEW;

ANTI-BACTERIAL AGENTS; BIOFILMS; CRITICAL ILLNESS; CROSS INFECTION; ENDOTOXINS; EXOTOXINS; FEMALE; FLAGELLA; HUMANS; INTENSIVE CARE UNITS; MALE; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; RISK FACTORS; SENSITIVITY AND SPECIFICITY; SURVIVAL RATE; VIRULENCE FACTORS;

EID: 67650446165     PISSN: 00903493     EISSN: 15300293     Source Type: Journal    
DOI: 10.1097/CCM.0b013e31819ff137     Document Type: Review

References (189)

1. Trautmann M, Lepper PM, Haller M: Ecology of Pseudomonas aeruginosa in the intensive care unit and the evolving role of water outlets as a reservoir of the organism. Am J Infect Control 2005; 33:S41-S49
2. Talbot GH, Bradley J, Edwards JE Jr, et al: Bad bugs need drugs: An update on the development pipeline from the Antimicrobial Availability Task Force of the Infectious Diseases Society of America. Clin Infect Dis 2006; 42:657-668
3. Sadikot RT, Blackwell TS, Christman JW, et al: Pathogen-host interactions in Pseudomonas aeruginosa pneumonia. Am J Respir Crit Care Med 2005; 171:1209-1223
4. Wine J: The genesis of cystic fibrosis in lung disease. J Clin Invest 1999; 103:309-312
5. Kipnis E, Sawa T, Wiener-Kronish J: Targeting mechanisms of Pseudomonas aeruginosa pathogenesis. Med Mal Infect 2006; 36:78-91
6. Kurahashi K, Kajikawa O, Sawa T, et al: Pathogenesis of septic shock in P. aeruginosa pneumonia. J Clin Invest 1999; 104: 743-750
7. Kudoh I, Wiener-Kronish JP, Hashimoto S, et al: Exoproduct secretions of P. aeruginosa strains influence severity of alveolar epithelial injury. Am J Physiol 1995; 268: 181-186
8. Lorenz E, Chemotti DC, Vandal K, et al: Toll-like receptor 2 represses nonpilus adhesion-induced signaling in acute infections with the Pseudomonas aeruginosa pilA mutant. Infect Immun 2004; 72: 4561-4569
9. Schultz MJ, Rijneveld W, Floruin S, et al: Role of interleukin-1 in the pulmonary immune response during Pseudomonas aeruginosa pneumonia. Am J Physiol Lung Cell Mol Physiol 2002; 282:285-290
10. Hauser AR, Cobb E, Bodi M, et al: Type III protein secretion is associated with poor clinical outcomes in patients with ventilator-associated pneumonia caused by Pseudomonas aeruginosa. Crit Care Med 2002; 30:521-528
11. Roy-Burman A, Savel RH, Racine S, et al: Type III protein secretion is associated with death in lower respiratory and systemic Pseudomonas aeruginosa infections. J Infect Dis 2001; 183:1767-1774
12. Rello J, Diaz E: Pneumonia in the intensive care unit. Crit Care Med 2003; 31: 2544-2551
13. Rello J, Rue M, Jubert P, et al: Survival in patients with nosocomial pneumonia: Impact of the severity of illness and the etio-logic agent. Crit Care Med 1997; 25: 1862-1867
14. Rello J, Jubert P, Valles J, et al: Evaluation of outcome for intubated patients with pneumonia due to Pseudomonas aeruginosa. Clin Infect Dis 1996; 23:973-978
15. Fagon JY, Chastre J, Vuagnat A, et al: Nosocomial pneumonia and mortality among patients in intensive care units. JAMA 1996; 275:866-869
16. Rice LB: Challenges in identifying new antimicrobial agents effective for treating infections with Acinetobacter baumannii and Pseudomonas aeruginosa. Clin Infect Dis 2006; 43(Suppl 2):S100-S105
17. Frank DW: The exoenzyme S regulon of Pseudomonas aeruginosa. Mol Microbiol 1997; 26:621-629
18. Holder IA, Neely AN, Frank DW: PcrV immunization enhances survival of burned Pseudomonas aeruginosa-infected mice. Infect Immun 2001; 69:5908-5910
19. Finck-Barbancon V, Goranson J, Zhu L, et al: ExoU expression by Pseudomonas aeruginosa correlates with acute cytotoxicity and epithelial injury. Mol Microbiol 1997; 25:547-557
20. Shaver CM, Hauser AR: Relative contributions of Pseudomonas aeruginosa ExoU, ExoS, and ExoT to virulence in the lung. Infect Immun 2004; 72:6969-6977
21. Coburn B, Sekirov I, Finlay BB: Type III secretion systems and disease. Clin Microbiol Rev 2007; 20:535-549
22. Yahr TL, Mende-Mueller LM, Friese MB, et al: Identification of type III secreted products of the Pseudomonas aeruginosa exoenzyme S regulon. J Bacteriol 1997; 179: 7165-7168
23. Hauser AR, Fleiszig S, Kang PJ, et al: Defects in type III secretion correlate with internalization of Pseudomonas aeruginosa by epithelial cells. Infect Immun 1998; 66: 1413-1420
24. Goehring UM, Schmidt G, Pederson KJ, et al: The N-terminal domain of Pseudomonas aeruginosa exoenzyme S is a GTPaseactivating protein for Rho GTPases. J Biol Chem 1999; 274:36369-36372
25. Deng Q, Sun J, Barbieri JT: Uncoupling Crk signal transduction by Pseudomonas exoenzyme T. J Biol Chem 2005; 280:35953-35960
26. Sun J, Barbieri JT: Pseudomonas aeruginosa ExoT ADP-ribosylates CT10 regulator of kinase (Crk) proteins. J Biol Chem 2003; 278:32794-32800
27. Barbieri JT, Sun J: Pseudomonas aeruginosa ExoS and ExoT. Rev Physiol Biochem Pharmacol 2004; 152:79-92
28. Feltman H, Schulert G, Khan S, et al: Prevalence of type III secretion genes in clinical and environmental isolates of Pseudomonas aeruginosa. Microbiology 2001; 147: 2659-2669
29. Zhang Y, Barbieri JT: A leucine-rich motif targets Pseudomonas aeruginosa ExoS within mammalian cells. Infect Immun 2005; 73:7938-7945
30. Zhang Y, Deng Q, Porath JA, et al: Plasma membrane localization affects the RhoGAP specificity of Pseudomonas ExoS. Cell Microbiol 2007; 9:2192-2201
31. Ottmann C, Yasmin L, Weyand M, et al: Phosphorylation-independent interaction between 14-3-3 and exoenzyme S: From structure to pathogenesis. EMBO J 2007; 26:902-913
32. Fu H, Coburn J, Collier RJ: The eukaryotic host factor that activates exoenzyme S of Pseudomonas aeruginosa is a member of the 14-3-3 protein family. Proc Natl Acad Sci USA 1993; 90:2320-2324
33. Zhang L, Wang H, Liu D, et al: Raf-1 kinase and exoenzyme S interact with 14-3-3zeta through a common site involving lysine 49. J Biol Chem 1997; 272:13717-13724
34. Masters SC, Pederson KJ, Zhang L, et al: Interaction of 14-3-3 with a nonphosphorylated protein ligand, exoenzyme S of Pseudomonas aeruginosa. Biochemistry 1999; 38:5216-5221
35. Coburn J, Kane AV, Feig L, et al: Pseudomonas aeruginosa exoenzyme S requires a eukaryotic protein for ADP-ribosyltrans-ferase activity. J Biol Chem 1991; 266: 6438-6446
36. Aitken A: 14-3-3 proteins: A historic overview. Semin Cancer Biol 2006; 16:162-172
37. Sato H, Frank DW: ExoU is a potent intracellular phospholipase. Mol Microbiol 2004; 53:1279-1290
38. Phillips RM, Six DA, Dennis EA, et al: In vivo phospholipase activity of the Pseudomonas aeruginosa cytotoxin ExoU and protection of mammalian cells with phospholipase A2 inhibitors. J Biol Chem 2003; 278: 41326-41332
39. Sato H, Feix JB, Frank DW: Identification of superoxide dismutase as a cofactor for the pseudomonas type III toxin, ExoU. Biochemistry 2006; 45:10368-10375
40. Rabin SD, Veesenmeyer JL, Bieging KT, et al: A C-terminal domain targets the Pseudomonas aeruginosa cytotoxin ExoU to the plasma membrane of host cells. Infect Immun 2006; 74:2552-2561
41. Rabin SDP, Hauser AR: Functional regions of the Pseudomonas aeruginosa cytotoxin ExoU. Infect Immun 2005; 73:573-582
42. Saliba AM, Nascimento DO, Silva MC, et al: Eicosanoid-mediated proinflammatory activity of Pseudomonas aeruginosa ExoU. Cell Microbiol 2005; 7:1811-1822
43. Yahr TL, Hovey AK, Kulich SM, et al: Transcriptional analysis of the Pseudomonas aeruginosa exoenzyme S structural gene. J Bacteriol 1995; 177:1169-1178
44. Hovey A, Frank DW: Analyses of the DNA-binding and transcriptional activation properties of ExsA, the transcriptional activator of the Pseudomonas aeruginosa exoenzyme S regulon. JBacteriol 1995; 177:4427-4436
45. Yahr TL, Wolfgang MC: Transcriptional regulation of the Pseudomonas aeruginosa type III secretion system. Mol Microbiol 2006; 62:631-640
46. McCaw ML, Lykken GL, Singh PK, et al: ExsD is a negative regulator of the Pseudomonas aeruginosa type III secretion regulon. Mol Microbiol 2002; 46: 1123-1133
47. Dasgupta N, Lykken GL, Wolfgang MC, et al: A novel anti-anti-activator mechanism regulates expression of the Pseudomonas aeruginosa type III secretion system. Mol Microbiol 2004; 53:297-308
48. Ha UH, Kim J, Badrane H, et al: An in vivo inducible gene of Pseudomonas aeruginosa encodes an anti-ExsA to suppress the type III secretion system. Mol Microbiol 2004; 54:307-320
49. Goranson J, Hovey AK, Frank DW: Functional analysis of exsC and exsB in regulation of exoenzyme S production by Pseudomonas aeruginosa. J Bacteriol 1997; 179: 1646-1654
50. Urbanowski ML, Lykken GL, Yahr TL: A secreted regulatory protein couples transcription to the secretory activity of the Pseudomonas aeruginosa type III secretion system. Proc Natl Acad Sci USA 2005; 102: 9930-9935
51. Rietsch A, Vallet-Gely I, Dove SL, et al: ExsE, a secreted regulator of type III secretion genes in Pseudomonas aeruginosa. Proc Natl Acad Sci USA 2005; 102: 8006-8011
52. Moss J, Ehrmantraut ME, Banwart BD, et al: Sera from adult patients with cystic fibrosis contain antibodies to Pseudomonas aeruginosa type III apparatus. Infect Immun 2001; 69:1185-1188
53. Wong-Beringer A, Wiener-Kronish J, Lynch S, et al: Comparison of type III secretion system virulence among fluoroquinolonesusceptible and -resistant clinical isolates of Pseudomonas aeruginosa. Clin Microbiol Infect 2008; 14:330-336
54. El Solh AA, Akinnusi ME, Wiener-Kronish JP, et al: Persistent infection with Pseudomonas aeruginosa in ventilator-associated pneumonia. Am J Respir Crit Care Med 2008; 178:513-519
55. Zhuo H, Yang K, Lynch SV, et al: Increased mortality of ventilated patients with endotracheal Pseudomonas aeruginosa without clinical signs of infection. Crit Care Med 2008; 36:2495-2503
56. Sawa T, Yahr T, Ohara M, et al: Active and passive immunization with the Pseudomonas V antigen protects against type III intoxication and lung injury. Nature Med 1999; 5:392-398
57. Neely AN, Holder IA, Wiener-Kronish JP, et al: Passive anti-PcrV treatment protects burned mice against Pseudomonas aeruginosa challenge. Burns 2005; 31:153-158
58. Shime N, Sawa T, Fujimoto J, et al: Therapeutic administration of anti-PcrV F(ab')(2) in sepsis associated with Pseudomonas aeruginosa. J Immunol 2001; 167: 5880-5886
59. Faure K, Fujimoto J, Shimabukuro DW, et al: Effects of monoclonal anti-PcrV antibody on Pseudomonas aeruginosa-induced acute lung injury in a rat model. J Immune Based Ther Vaccines 2003; 1:1-9
60. Frank DW, Vallis A, Wiener-Kronish JW, et al: Generation and characterization of a protective monoclonal antibody to Pseudomonas aeruginosa PcrV. J Infect Dis 2002; 186:64-73
61. Imamura Y, Yanagihara K, Fukuda Y, et al: Effect of anti-PcrV antibody in a murine chronic airway Pseudomonas aeruginosa infection model. Eur Respir J 2007; 29: 965-968
62. Lee VT, Pukatzki S, Sato H, et al: Pseudolipasin A is a specific inhibitor for phospholipase A2 activity of Pseudomonas aeruginosa cytotoxin ExoU. Infect Immun 2007; 75:1089-1098
63. Arnoldo A, Curak J, Kittanakom S, et al: Identification of small molecule inhibitors of Pseudomonas aeruginosa exoenzyme S using a yeast phenotypic screen. PLoS Genet 2008; 4:e1000005
64. Draper MP, Garrity-Ryan LK, Donovan P, et al: A novel anti-virulence approach for treatment of pneumonia caused by Pseudomonas aeruginosa 47th ASM Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago 2007, pp Abstract F2-968a
65. Juhas M, Eberl L, Tummler B: Quorum sensing: the power of cooperation in the world of Pseudomonas. Environ Microbiol 2005; 7:459-471
66. Ochsner UA, Koch AK, Fiechter A, et al: Isolation and characterization of a regulatory gene affecting rhamnolipid biosurfactant synthesis in Pseudomonas aeruginosa. J Bacteriol 1994; 176:2044-2054
67. Latifi A, Winson MK, Foglino M, et al: Multiple homologues of LuxR and LuxI control expression of virulence determinants and secondary metabolites through quorum sensing in Pseudomonas aeruginosa PAO1. Mol Microbiol 1995; 17:333-343
68. Winson MK, Camara M, Latifi A, et al: Multiple N-acyl-L-homoserine lactone signal molecules regulate production of virulence determinants and secondary metabolites in Pseudomonas aeruginosa. Proc Natl Acad Sci USA 1995; 92:9427-9431
69. Brint JM, Ohman DE: Synthesis of multiple exoproducts in Pseudomonas aeruginosa is under the control of RhlR-RhlI, another set of regulators in strain PAO1 with homology to the autoinducer-responsive LuxR-LuxI family. J Bacteriol 1995; 177:7155-7163
70. Toder DS, Gambello MJ, Iglewski BH: Pseudomonas aeruginosa LasA: A second elastase under the transcriptional control of lasR. Mol Microbiol 1991; 5:2003-2010
71. Passador L, Cook JM, Gambello MJ, et al: Expression of Pseudomonas aeruginosa vir- ulence genes requires cell-to-cell communication. Science 1993; 260:1127-1130
72. Chapon-Herve V, Akrim M, Latifi A, et al: Regulation of the xcp secretion pathway by multiple quorum-sensing modulons in Pseudomonas aeruginosa. Mol Microbiol 1997; 24:1169-1178
73. Schuster M, Lostroh CP, Ogi T, et al: Identification, timing, and signal specificity of Pseudomonas aeruginosa quorum-controlled genes: A transcriptome analysis. J Bacteriol 2003; 185:2066-2079
74. Bjarnsholt T, Givskov M: The role of quorum sensing in the pathogenicity of the cunning aggressor Pseudomonas aeruginosa. Anal Bioanal Chem 2007; 387: 409-414
75. Gambello MJ, Iglewski BH: Cloning and characterization of the Pseudomonas aeruginosa lasR gene, a transcriptional activator of elastase expression. J Bacteriol 1991; 173:3000-3009
76. Pesci EC, Milbank JB, Pearson JP, et al: Quinolone signaling in the cell-to-cell communication system of Pseudomonas aerugi-nosa. Proc Natl Acad Sci USA 1999; 96: 11229-11234
77. Dong YH, Wang LY, Zhang LH: Quorumquenching microbial infections: Mechanisms and implications. Philos Trans R Soc Lond B Biol Sci 2007; 362:1201-1211
78. Stoltz DA, Ozer EA, Ng CJ, et al: Paraoxonase-2 deficiency enhances Pseudomonas aeruginosa quorum sensing in murine tracheal epithelia. Am J Physiol Lung Cell Mol Physiol 2007; 292:L852-L860
79. Ozer EA, Pezzulo A, Shih DM, et al: Human and murine paraoxonase 1 are host modulators of Pseudomonas aeruginosa quorumsensing. FEMS Microbiol Lett 2005; 253: 29-37
80. Yang F, Wang LH, Wang J, et al: Quorum quenching enzyme activity is widely conserved in the sera of mammalian species. FEBS Lett 2005; 579:3713-3717
81. Hoang TT, Schweizer HP: Characterization of Pseudomonas aeruginosa enoyl-acyl carrier protein reductase (FabI): A target for the antimicrobial triclosan and its role in acylated homoserine lactone synthesis. J Bacteriol 1999; 181:5489-5497
82. Reimmann C, Ginet N, Michel L, et al: Genetically programmed autoinducer destruction reduces virulence gene expression and swarming motility in Pseudomonas aeruginosa PAO1. Microbiology 2002; 148: 923-932
83. Lin YH, Xu JL, Hu J, et al: Acyl-homoserine lactone acylase from Ralstonia strain XJ12B represents a novel and potent class of quorum-quenching enzymes. Mol Microbiol 2003; 47:849-860
84. Wu H, Song Z, Hentzer M, et al: Synthetic furanones inhibit quorum-sensing and enhance bacterial clearance in Pseudomonas aeruginosa lung infection in mice. J Antimicrob Chemother 2004; 53:1054-1061
85. Hentzer M, Wu H, Andersen JB, et al: At- tenuation of Pseudomonas aeruginosa virulence by quorum sensing inhibitors. EMBO J 2003; 22:3803-3815
86. Hentzer M, Riedel K, Rasmussen TB, et al: Inhibition of quorum sensing in Pseudomonas aeruginosa biofilm bacteria by a halogenated furanone compound. Microbiology 2002; 148:87-102
87. Kim C, Kim J, Park HY, et al: Furanone derivatives as quorum-sensing antagonists of Pseudomonas aeruginosa. Appl Microbiol Biotechnol 2008; 80:37-47
88. Hoiby N, Krogh Johansen H, Moser C, et al: Pseudomonas aeruginosa and the in vitro and in vivo biofilm mode of growth. Microbes Infect 2001; 3:23-35
89. Proctor RA, von Eiff C, Kahl BC, et al: Small colony variants: A pathogenic form of bacteria that facilitates persistent and recurrent infections. Nat Rev Microbiol 2006; 4:295-305
90. Haussler S, Ziegler I, Lottel A, et al: Highly adherent small-colony variants of Pseudomonas aeruginosa in cystic fibrosis lung infection. J Med Microbiol 2003; 52: 295-301
91. Deziel E, Comeau Y, Villemur R: Initiation of biofilm formation by Pseudomonas aeruginosa 57RP correlates with emergence of hyperpiliated and highly adherent phenotypic variants deficient in swimming, swarming, and twitching motilities. J Bacteriol 2001; 183:1195-1204
92. Kirisits MJ, Prost L, Starkey M, et al: Characterization of colony morphology variants isolated from Pseudomonas aeruginosa bio-films. Appl Environ Microbiol 2005; 71: 4809-4821
93. Mah TF, Pitts B, Pellock B, et al: A genetic basis for Pseudomonas aeruginosa biofilm antibiotic resistance. Nature 2003; 426: 306-310
94. Kollef MH, Afessa B, Anzueto A, et al: Silvercoated endotracheal tubes and incidence of ventilator-associated pneumonia: The NASCENT randomized trial. JAMA 2008; 300: 805-813
95. Rello J, Kollef M, Diaz E, et al: Reduced burden of bacterial airway colonization with a novel silver-coated endotracheal tube in a randomized multiple-center feasibility study. Crit Care Med 2006; 34:2766-2772
96. Singh PK, Parsek MR, Greenberg EP, et al: A component of innate immunity prevents bacterial biofilm development. Nature 2002; 417:552-555
97. Rasmussen TB, Skindersoe ME, Bjarnsholt T, et al: Identity and effects of quorumsensing inhibitors produced by Penicillium species. Microbiology 2005; 151:1325-1340
98. Adonizio A, Kong KF, Mathee K: Inhibition of quorum sensing-controlled virulence factor production in Pseudomonas aeruginosa by South Florida plant extracts. Antimicrob Agents Chemother 2008; 52:198-203
99. Hu JF, Garo E, Goering MG, et al: Bacterial biofilm inhibitors from Diospyros dendo. J Nat Prod 2006; 69:118-120
100. Geske GD, Wezeman RJ, Siegel AP, et al: Small molecule inhibitors of bacterial quorum sensing and biofilm formation. J Am Chem Soc 2005; 127:12762-12763
101. Banin E, Brady KM, Greenberg EP: Chelator-induced dispersal and killing of Pseudomonas aeruginosa cells in a biofilm. Appl Environ Microbiol 2006; 72:2064-2069
102. Alkawash MA, Soothill JS, Schiller NL: Alginate lyase enhances antibiotic killing of mucoid Pseudomonas aeruginosa in biofilms. APMIS 2006; 114:131-138
103. Hatch RA, Schiller NL: Alginate lyase promotes diffusion of aminoglycosides through the extracellular polysaccharide of mucoid Pseudomonas aeruginosa. Antimicrob Agents Chemother 1998; 42:974-977
104. Blenkinsopp SA, Khoury AE, Costerton JW: Electrical enhancement of biocide efficacy against Pseudomonas aeruginosa biofilms. Appl Environ Microbiol 1992; 58: 3770-3773
105. Jass J, Lappin-Scott HM: The efficacy of antibiotics enhanced by electrical currents against Pseudomonas aeruginosa biofilms. J Antimicrob Chemother 1996; 38: 987-1000
106. Barraud N, Hassett DJ, Hwang SH, et al: Involvement of nitric oxide in biofilm dispersal of Pseudomonas aeruginosa. J Bacteriol 2006; 188:7344-7353
107. Arora SK, Ritchings BW, Almira EC, et al:. The Pseudomonas aeruginosa flagellar cap protein, FliD, is responsible for mucin adhesion. Infect Immun 1998; 66:1000-1007
108. Gewirtz AT, Navas TA, Lyons S, et al: Cutting edge: Bacterial flagellin activates basolaterally expressed TLR5 to induce epithelial proinflammatory gene expression. J Immunol 2001; 167:1882-1885
109. O'Toole GA, Kolter R: Flagellar and twitching motility are necessary for Pseudomonas aeruginosa biofilm development. Mol Microbiol 1998; 30:295-304
110. Montie TC, Doyle-Huntzinger D, Craven RC, et al: Loss of virulence associated with absence of flagellum in an isogenic mutant of Pseudomonas aeruginosa in the burnedmouse model. Infect Immun 1982; 38: 1296-1298
111. Fleiszig SM, Arora SK, Van R, et al: FlhA, a component of the flagellum assembly apparatus of Pseudomonas aeruginosa, plays a role in internalization by corneal epithelial cells. Infect Immun 2001; 69:4931-4937
112. Zhang J, Xu K, Ambati B, et al: Toll-like receptor 5-mediated corneal epithelial inflammatory responses to Pseudomonas aeruginosa flagellin. Invest Ophthalmol Vis Sci 2003; 44:4247-4254
113. Hayashi F, Smith KD, Ozinsky A, et al: The innate immune response to bacterial flagellin is mediated by Toll-like receptor 5. Nature 2001; 410:1099-1103
114. Rumbo M, Nempont C, Kraehenbuhl JP, et al: Mucosal interplay among commensal and pathogenic bacteria: Lessons from flagellin and Toll-like receptor 5. FEBS Lett 2006; 580:2976-2984
115. Zhang Z, Louboutin JP, Weiner DJ, et al: Human airway epithelial cells sense Pseudomonas aeruginosa infection via recognition of flagellin by Toll-like receptor 5. Infect Immun 2005; 73:7151-7160
116. Wolfgang MC, Jyot J, Goodman A, et al: Pseudomonas aeruginosa regulates flagellin expression as part of a global response to airway fluid from cystic fibrosis patients. Proc Natl Acad Sci USA 2004; 101: 6664-6668
117. Palmer KL, Mashburn LM, Singh PK, et al: Cystic fibrosis sputum supports growth and cues key aspects of Pseudomonas aeruginosa physiology. J Bacteriol 2005; 187: 5267-5277
118. Sonawane A, Jyot J, During R, et al: Neutrophil elastase, an innate immunity effector molecule, represses flagellin transcription in Pseudomonas aeruginosa. Infect Immun 2006; 74:6682-6689
119. Jyot J, Sonawane A, Wu W, et al: Genetic mechanisms involved in the repression of flagellar assembly by Pseudomonas aeruginosa in human mucus. Mol Microbiol 2007; 63:1026-1038
120. Smith EE, Buckley DG, Wu Z, et al: Genetic adaptation by Pseudomonas aeruginosa to the airways of cystic fibrosis patients. Proc Natl Acad Sci USA 2006; 103:8487-8492
121. Mahenthiralingam E, Campbell ME, Speert DP: Nonmotility and phagocytic resistance of Pseudomonas aeruginosa isolates from chronically colonized patients with cystic fibrosis. Infect Immun 1994; 62:596-605
122. Landsperger WJ, Kelly-Wintenberg KD, Montie TC, et al: Inhibition of bacterial motility with human antiflagellar monoclonal antibodies attenuates Pseudomonas aeruginosa-induced pneumonia in the immunocompetent rat. Infect Immun 1994; 62: 4825-4830
123. Holder IA, Naglich JG: Experimental studies of the pathogenesis of infections due to Pseudomonas aeruginosa: Immunization using divalent flagella preparations. J Trauma 1986; 26:118-122
124. Doring G, Meisner C, Stern M: A double-blind randomized placebo-controlled phase III study of a Pseudomonas aeruginosa fla-gella vaccine in cystic fibrosis patients. Proc Natl Acad Sci USA 2007; 104:11020-11025
125. Tang H, Kays M, Prince A: Role of Pseudomonas aeruginosa pili in acute pulmonary infection. Infect Immun 1995; 63: 1278-1285
126. Chi E, Mehl T, Nunn D, et al: Interaction of Pseudomonas aeruginosa with A549 pneu-mocyte cells. Infect Immun 1991; 59: 822-828
127. Kao DJ, Churchill ME, Irvin RT, et al: Animal protection and structural studies of a consensus sequence vaccine targeting the receptor binding domain of the type IV pilus of Pseudomonas aeruginosa. J Mol Biol 2007; 374:426-442
128. Ohama M, Hiramatsu K, Miyajima Y, et al: Intratracheal immunization with pili protein protects against mortality associated with Pseudomonas aeruginosa pneumonia in mice. FEMS Immunol Med Microbiol 2006; 47:107-115
129. Feldman M, Bryan R, Rajan S, et al: Role of flagella in pathogenesis of Pseudomonas aeruginosa pulmonary infection. Infect Immun 1998; 66:43-51
130. Balloy V, Verma A, Kuravi S, et al: The role of flagellin versus motility in acute lung disease caused by Pseudomonas aeruginosa. J Infect Dis 2007; 196:289-296
131. Doring G, Dorner F: A multicenter vaccine trial using the Pseudomonas aeruginosa flagella vaccine IMMUNO in patients with cystic fibrosis. Behring Inst Mitt 1997; 98: 338-344
132. Danner RL, Natanson C, Elin RJ, et al: Pseudomonas aeruginosa compared with Escherichia coli produces less endotoxemia but more cardiovascular dysfunction and mortality in a canine model of septic shock. Chest 1990; 98:1480-1487
133. Moskowitz SM, Ernst RK, Miller SI: PmrAB, a two-component regulatory system of Pseudomonas aeruginosa that modulates resistance to cationic antimicrobial peptides and addition of aminoarabinose to lipid A. J Bacteriol 2004; 186:575-579
134. Pier GB, Ames P: Mediation of the killing of rough, mucoid isolates of Pseudomonas aeruginosa from patients with cystic fibrosis by the alternative pathway of complement. J Infect Dis 1984; 150:223-228
135. Zuercher AW, Horn MP, Que JU, et al: Antibody responses induced by long-term vaccination with an octovalent conjugate Pseudomonas aeruginosa vaccine in children with cystic fibrosis. FEMS Immunol Med Microbiol 2006; 47:302-308
136. Lang AB, Rudeberg A, Schoni MH, et al: Vaccination of cystic fibrosis patients against Pseudomonas aeruginosa reduces the proportion of patients infected and delays time to infection. Pediatr Infect Dis J 2004; 23:504-510
137. Lai Z, Kimmel R, Petersen S, et al: Multivalent human monoclonal antibody preparation against Pseudomonas aeruginosa derived from transgenic mice containing human immunoglobulin loci is protective against fatal pseudomonas sepsis caused by multiple serotypes. Vaccine 2005; 23: 3264-3271
138. Simpson JA, Smith SE, Dean RT: Scavenging by alginate of free radicals released by macrophages. Free Radic Biol Med 1989; 6:347-353
139. Cabral DA, Loh BA, Speert DP: Mucoid Pseudomonas aeruginosa resists nonopsonic phagocytosisi by human neutrophils and macrophages. Paediatr Res 1987; 22: 429-431
140. Kashef N, Behzadian-Nejad Q, NajarPeerayeh S, et al: Synthesis and characterization of Pseudomonas aeruginosa alg- inate-tetanus toxoid conjugate. J Med Microbiol 2006; 55:1441-1446
141. Theilacker C, Coleman FT, Mueschenborn S, et al: Construction and characterization of a Pseudomonas aeruginosa mucoid exopolysaccharide- alginate conjugate vaccine. Infect Immun 2003; 71:3875-3884
142. Pier GB, Boyer D, Preston M, et al: Human monoclonal antibodies to Pseudomonas aeruginosa alginate that protect against infection by both mucoid and nonmucoid strains. J Immunol 2004; 173:5671-5678
143. Lee VT, Smith RS, Tummler B, et al: Activities of Pseudomonas aeruginosa effectors secreted by the type III secretion system in vitro and during infection. Infection and immunity 2005; 73:1695-1705
144. Vance RE, Rietsch A, Mekalanos JJ: Role of the type III secreted exoenzymes S, T, and Y in systemic spread of Pseudomonas aeruginosa PAO1 in vivo. Infect Immun 2005; 73:1706-1713
145. Park PW, Pier GB, Hinkes MT, et al: Exploitation of syndecan-1 shedding by Pseudomonas aeruginosa enhances virulence. Nature 2001; 411:98-102
146. Azghani AO: Pseudomonas aeruginosa and epithelial permeability: Role of virulence factors elastase and exotoxin A. Am J Respir Cell Mol Biol 1996; 15:132-140
147. Matsumoto T, Tateda K, Furuya N, et al: Efficacies of alkaline protease, elastase and exotoxin A toxoid vaccines against gutderived Pseudomonas aeruginosa sepsis in mice. J Med Microbiol 1998; 47:303-308
148. Sokol PA, Kooi C, Hodges RS, et al: Immunization with a Pseudomonas aeruginosa elastase peptide reduces severity of experimental lung infections due to P. aeruginosa or Burkholderia cepacia. J Infect Dis 2000; 181:1682-1692
149. Nicas T, Iglewski BH: The contribution of exoproducts to virulence of Pseudomonas aeruginosa. Can J Microbiol 1985; 31: 387-392
150. Guzzo J, Pages JM, Duong F, et al: Pseudomonas aeruginosa alkaline protease: Evidence for secretion genes and study of secretion mechanism. J Bacteriol 1991; 173: 5290-5297
151. Miyazaki S, Matsumoto T, Tateda K, et al: Role of exotoxin A in inducing severe Pseudomonas aeruginosa infections in mice. J Med Microbiol 1995; 43:169-175
152. Denis-Mize KS, Price BM, Baker NR, et al: Analysis of immunization with DNA encoding Pseudomonas aeruginosa exotoxin A. FEMS Immunol Med Microbiol 2000; 27: 147-154
153. Hertle R, Mrsny R, Fitzgerald DJ: Dualfunction vaccine for Pseudomonas aeruginosa: Characterization of chimeric exotoxin A-pilin protein. Infect Immun 2001; 69: 6962-6969
154. El-Zaim HS, Chopra AK, Peterson JW, et al: Protection against exotoxin A (ETA) and Pseudomonas aeruginosa infection in mice with ETA-specific antipeptide antibodies. Infect Immun 1998; 66:5551-5554
155. Pearson JP, Feldman M, Iglewski BH, et al: Pseudomonas aeruginosa cell-to-cell signaling is required for virulence in a model of acute pulmonary infection. Infect Immun1 2000; 68:4331-4334
156. Rumbaugh KP, Griswold JA, Iglewski BH, et al: Contribution of quorum sensing to the virulence of Pseudomonas aeruginosa in burn wound infections. Infect Immun 1999; 67:5854-5862
157. Jesaitis AJ, Franklin MJ, Berglund D, et al: Compromised host defense on Pseudomonas aeruginosa biofilms: Characterization of neutrophil and biofilm interactions. J Immunol 2003; 171:4329-4339
158. Cochran WL, McFeters GA, Stewart PS: Reduced susceptibility of thin Pseudomonas aeruginosa biofilms to hydrogen peroxide and monochloramine. J Appl Microbiol 2000; 88:22-30
159. Doring G, Pier GB: Vaccines and immunotherapy against Pseudomonas aeruginosa. Vaccine 2008; 26:1011-1024
160. Mandell GL, Bennett JE, Dolin R: Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases, Sixth Edition. Philadelphia (PA): Elsevier; 2005
161. Holder IA. Pseudomonas immunotherapy: A historical overview. Vaccine 2004; 22: 831-839
162. Rumbaugh KP, Sawa T, Wiener-Kronish JP: New perspectives on prevention and management of Pseudomonas aeruginosa infections. In: Severe Infections Caused by Pseudomonas aeruginosa. Edited by Hauser AR, Rello J, vol. 7. Boston: Kluwer Academic Publishers, 2003, pp 183-201
163. Persson T, Hansen TH, Rasmussen TB, et al: Rational design and synthesis of new quorum-sensing inhibitors derived from acylated homoserine lactones and natural products from garlic. Org Biomol Chem 2005; 3:253-262
164. Smith KM, Bu Y, Suga H: Library screening for synthetic agonists and antagonists of a Pseudomonas aeruginosa autoinducer. Chem Biol 2003; 10:563-571
165. Smith KM, Bu Y, Suga H: Induction and inhibition of Pseudomonas aeruginosa quorum sensing by synthetic autoinducer analogs. Chem Biol 2003; 10:81-89
166. Ishida T, Ikeda T, Takiguchi N, et al: Inhibition of quorum sensing in Pseudomonas aeruginosa by N-acyl cyclopentylamides. Appl Environ Microbiol 2007; 73:3183-3188
167. Muh U, Schuster M, Heim R, et al: Novel Pseudomonas aeruginosa quorum-sensing inhibitors identified in an ultra-high-throughput screen. Antimicrob Agents Chemother 2006; 50:3674-3679
168. Rasmussen TB, Bjarnsholt T, Skindersoe ME, et al: Screening for quorum-sensing inhibitors (QSI) by use of a novel genetic system, the QSI selector. J Bacteriol 2005; 187:1799-1814
169. Muh U, Hare BJ, Duerkop BA, et al: A struc- turally unrelated mimic of a Pseudomonas aeruginosa acyl-homoserine lactone quorum-sensing signal. Proc Natl Acad Sci USA 2006; 103:16948-16952
170. Manefield M, Rasmussen TB, Henzter M, et al: Halogenated furanones inhibit quorum sensing through accelerated LuxR turnover. Microbiology 2002; 148:1119-1127
171. Hjelmgaard T, Persson T, Rasmussen TB, et al: Synthesis of furanone-based natural product analogues with quorum sensing antagonist activity. Bioorg Med Chem 2003; 11:3261-3271
172. Bjarnsholt T, Jensen PO, Burmolle M, et al: Pseudomonas aeruginosa tolerance to to-bramycin, hydrogen peroxide and polymorphonuclear leukocytes is quorum-sensing dependent. Microbiology 2005; 151: 373-383
173. Bjarnsholt T, Jensen PO, Rasmussen TB, et al: Garlic blocks quorum sensing and promotes rapid clearing of pulmonary Pseudomonas aeruginosa infections. Microbiology 2005; 151:3873-3880
174. Tateda K, Comte R, Pechere J-C, et al: Azithromycin inhibits quorum sensing in Pseudomonas aeruginosa. Antimicrob Agents Chemother 2001; 45:1930-1933
175. Parsek MR, Val DL, Hanzelka BL, et al: Acyl homoserine-lactone quorum-sensing signal generation. Proc Natl Acad Sci USA 1999; 96:4360-4365
176. Veenstra DL, Saint S, Saha S, et al: Efficacy of antiseptic-impregnated central venous catheters in preventing catheter-related bloodstream infection: A meta-analysis. JAMA 1999; 281:261-267
177. Ardehali R, Shi L, Janatova J, et al: The effect of apo-transferrin on bacterial adhesion to biomaterials. Artif Organs 2002; 26: 512-520
178. Yang L, Barken KB, Skindersoe ME, et al: Effects of iron on DNA release and biofilm development by Pseudomonas aeruginosa. Microbiology 2007; 153:1318-1328
179. Musk DJ, Banko DA, Hergenrother PJ: Iron salts perturb biofilm formation and disrupt existing biofilms of Pseudomonas aeruginosa. Chem Biol 2005; 12:789-796
180. Cartagena E, Colom OA, Neske A, et al: Effects of plant lactones on the production of biofilm of Pseudomonas aeruginosa. Chem Pharm Bull 2007; 55:22-25
181. Gillis RJ, Iglewski BH: Azithromycin retards Pseudomonas
182. Yasuda H, Ajiki Y, Koga T, et al: Interaction between biofilms formed by Pseudomonas aeruginosa and clarithromycin. Antimicrob Agents Chemother 1993; 37:1749-1755
183. Wozniak DJ, Keyser R: Effects of subinhibitory concentrations of macrolide antibiotics on Pseudomonas aeruginosa. Chest 2004; 125: 62S-69S.
184. Ishikawa J, Horii T: Effects of mupirocin at subinhibitory concentrations on biofilm formation in Pseudomonas aeruginosa. Chemotherapy 2005; 51:361-362
185. Huigens RW III, Ma L, Gambino C, et al: Control of bacterial biofilms with marine alkaloid derivatives. Mol Biosyst 2008; 4:614-621
186. Huigens RW III, Richards JJ, Parise G, et al: Inhibition of Pseudomonas aeruginosa biofilm formation with Bromoageliferin analogues. J Am Chem Soc 2007; 129: 6966-6967
187. Richards JJ, Ballard TE, Melander C: Inhibition and dispersion of Pseudomonas aeruginosa biofilms with reverse amide 2-aminoimidazole oroidin analogues. Org Biomol Chem 2008; 6:1356-1363
188. Junker LM, Clardy J: High-throughput screens for small-molecule inhibitors of Pseudomonas aeruginosa biofilm development. Antimicrob Agents Chemother 2007; 51:3582-3590
189. Li F, Yu J, Yang H, et al: Effects of ambroxol on alginate of mature Pseudomonas aeruginosa biofilms. Curr Microbiol 2008; 57:1-7